超级效应还是方法学缺陷：质疑胰高血糖素样肽-1受体激动剂与癌症的关系。对迈尔·G·A、拉特曼·W、库斯·O [信件]的回复 - Suppr | 超能文献

相似文献

1

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. Reply to Maier GA, Rathmann W, Kuß O [letter].超级效应还是方法学缺陷：质疑胰高血糖素样肽-1受体激动剂与癌症的关系。对迈尔·G·A、拉特曼·W、库斯·O [信件]的回复

Diabetologia. 2025 Sep 4. doi: 10.1007/s00125-025-06526-z.

2

Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes.孕前使用胰高血糖素样肽-1受体激动剂与不良产科结局风险降低相关。

Am J Obstet Gynecol. 2025 Jan 21. doi: 10.1016/j.ajog.2025.01.019.

3

Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例组合：一项系统评价和荟萃分析。

Endocrine. 2017 Jun;56(3):485-494. doi: 10.1007/s12020-017-1293-6. Epub 2017 Apr 12.

4

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.替尔泊肽，一种双重葡萄糖依赖性胰岛素促分泌多肽/胰高血糖素样肽 1 受体激动剂，在肥胖 2 型糖尿病 db/db 小鼠中对胰岛β细胞和肝脂肪变性具有有利影响。

Diabetes Obes Metab. 2024 Dec;26(12):5982-5994. doi: 10.1111/dom.15972. Epub 2024 Sep 30.

5

Glucagon-like peptide 1 (GLP-1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials.胰高血糖素样肽1（GLP-1）受体激动剂在孕期的使用：来自监管临床试验的安全性数据。

Diabetes Obes Metab. 2025 May 6. doi: 10.1111/dom.16437.

6

Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.胰岛素-胰高血糖素样肽-1 受体激动剂接力和胰高血糖素样肽-1 受体激动剂一线治疗方案在 2 型糖尿病患者中的随机、开放标签试验研究。

J Diabetes Investig. 2022 Jun;13(6):965-974. doi: 10.1111/jdi.13749. Epub 2022 Feb 8.

7

A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.多囊卵巢综合征患者 GLP-1 对人体测量学、代谢和内分泌参数影响的系统评价

Womens Health (Lond). 2024 Jan-Dec;20:17455057241234530. doi: 10.1177/17455057241234530.

8

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的胃肠道癌症风险

Diabetologia. 2025 Jun 5. doi: 10.1007/s00125-025-06453-z.

9

Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。

Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.

10

The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述

Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.

本文引用的文献

1

Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的胃肠道癌症风险

Diabetologia. 2025 Jun 5. doi: 10.1007/s00125-025-06453-z.

2

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.胰高血糖素样肽 1 受体激动剂与 2 型糖尿病患者的 13 种肥胖相关癌症。

JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.

3

Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes.